Vanguard Capital Management
FBIO icon

Vanguard Capital Management’s Fortress Biotech FBIO Stock Holding History

Vanguard Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Buy
1,037,203
+71,173
+7% +$184K ﹤0.01% 3269
2026
Q1 		$2.7M Buy
+966,030
New +$3.28M ﹤0.01% 3265

Other funds holding FBIO

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Vanguard Capital Management's FBIO Position: Q2 2026 in Review

Vanguard Capital Management increased its Fortress Biotech (FBIO) stake by 7.4% in Q2 2026, buying an estimated $184K and bringing the position to 1,037,203 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3269.

Vanguard Capital Management first reported a position in FBIO in Q1 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.

  • Vanguard Capital Management held 1,037,203 shares of Fortress Biotech worth $3.17M as of Q2 2026.
  • Vanguard Capital Management bought 71,173 Fortress Biotech shares in Q2 2026, an estimated $184K.
  • Fortress Biotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3269 holding.
  • Vanguard Capital Management first reported a position in Fortress Biotech in Q1 2026 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.